The Global Anti-Fungal Drugs Market was valued at USD 16.5 Billion in 2023 and is estimated to reach USD21.93 Billion by 2032, growing at a CAGR of 3.54% from 2023 to 2032.
Scope of the market:
Fungi are microorganisms that can live in any kind of environment. An infection can occur through an unhygienic environment or can also enter into body through inhalation. Fungal infection comes with both systemic and superficial infections that occur to the eyes, skin, vagina, and mouth. The rising prevalence of fungal infections such as candidiasis and aspergillosis isa major reason for this market to boom.
Anti-fungal infection mainly known as anti-mycotic medication, is a fungus used to prevent and treat mycosis such as candidiasis, ringworm, and others. For such diseases, mainly anti-fungal drugs are available to cure fungal infections. They are mostly given orally, in powder, or as an ointment.
Increasing incidence of fungal infection, spreading awareness for myriad fungal infections, and growing prevalence of candidiasis and aspergillosis are the major factors that are driving this anti-fungal drug market globally. Furthermore, the increasing number of drug approvals is giving several opportunities for expansion in the forecast period. A rising number of over-the-counter (OTC) anti-fungaldrugs has gained popularity in drugs like econazole, miconazole, amorolfine, and others have resulted in heavy consumption by patients of these OTC. Some side effects of this drug are anticipated to hinder the adoption of this drug therefore restraining this market growth.
Economic Impact of Covid-19:
The analysis of the COVID-19 recovery trajectory provides an overview of the main strategies that industries are implementing to respond to and recover from the economic crisis. It alsofocuses on the post-pandemic and pre-pandemic era of the Global Anti-Fungal Drugs Market through PEST analysis, SWOT, Quantitative and Qualitative analysis, Attractive analysis, and DROs.
Key Players:
- GlaxoSmithKline
- Bayer AG
- Abbott Laboratories
- Novartis
- Astellas Pharma Inc.,
- Merck & Co. Inc
- Glenmark Pharmaceuticals Ltd
- Pfizer Inc.
- Gilead Science Inc.,
- Sanofi S.A.
- Alembic Pharmaceuticals Ltd
- Enzon Pharmaceuticals, Inc.,
- Leadiant Bioscience Inc.
- Aurobindo Pharma USA
- Cipla Inc.,
- Others
The above key players in the Global Anti-Fungal Drugs Market can be changed according to client’s requirements.
Recent Developments in Global Anti-Fungal Drugs Market.
In 2023, Sandoz announced an agreement to acquire leading antifungal agent Mycamine from Astellas. Mycamine will support Sandoz in a global program to combat antimicrobial resistance (AMR). Mycamine is the leading global echinocandin one of the 3 major classes of anti-fungal agents, with a global patient base of 2 million. Globally, it is the therapy used in ICUs and hospitals, a proven prophylactic in oncology and hematology patients, and widely used in organ transplants.
March 2023, GSK and SCYNEXIS have announced an exclusive agreement to commercialize and further develop Brexafemme, a novel first-in-class medicine to treat fungal infection. Brexafemme complements GSK’s industry-leading infectious disease portfolio with anFDA-approved treatment for vulvovaginal candidiasis (VVC) and a reduction in the incidence of recurrent VVC. 75% of womenare affected by VVC.
According to NCBI, approximately 60 million Indians are affected by serious fungal infections. Tinea capitis and recurrent VVC account for 49 million.
According to Wionews, global fungal infections cause an alarm of 3.8 million deaths annually, i.e. 6.8% of global mortality.
Global Anti-Fungal Drugs Market Key Benefits:
- The report provides information regarding key drivers, restraints, and opportunities with impact analysis.
- Quantitative and Qualitative analysis of the current market.
- Estimations for the forecast period 2032.
- Historical data and forecast data.
- Recent developments and trends in the market.
- Market share of the market players, company profiles, SWOT analysis, and competitive landscape.
- Covid-19 Impact analysis
Global Anti-Fungal Drugs MarketSegmentation:
By Drug Type:
- Azoles
- Polyenes
- Allylamines
- Echinocandins
- Others
By Indication:
- Candidiasis
- Aspergillosis
- Dermatophytosis
- Other Indications
By Dosage Forms:
- Tablets
- Ointments
- Powder
- Injections
By Route of Administration:
- Oral
- Parenteral
- Topical
By Distribution Channel:
- Retail
- Hospital
- Online
Based on Region:
Asia-Pacific
- Japan
- China
- India
- Australia
- New Zealand
- Rest of Asia-Pacific
North America
- US
- Canada
- Mexico
Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Europe
The rest of the World
Each of the market segments has been analysed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and competitive analysis.
Research Scope:
|
Report Scope |
Details |
|
Base Year |
2023 |
|
Historical Years |
2019 to 2022 |
|
Forecast Years |
2023 to 2033 |
|
Market Size 2023 |
USD 16.5BN |
|
Market Revenue 2032 |
USD 21.93 BN |
|
Growth Rate 2023- 2032 |
3.54% |
|
Report Coverage |
Trends, SWOT Analysis, Competitive Landscape, DROs, Revenue Forecast, PEST Analysis. |
|
Segments Covered |
Drug Type, Indication, Dosage Form,Route of Administration, Distribution Channel, Region |
|
Companies Mentioned |
GlaxoSmithKline, Bayer AG, Abbott Laboratories, Novartis, Astellas Pharma Inc.,Merck & Co. Inc, Glenmark Pharmaceuticals Ltd, Pfizer Inc., Gilead Science Inc.,Sanofi S.A., Alembic Pharmaceuticals Ltd, Enzon Pharmaceuticals, Inc., Leadiant Bioscience Inc., Aurobindo Pharma USA, Cipla Inc., |
|
Customization |
Yes |
Regional Analysis:
North America dominated the Anti-Fungal Drugs Market in 2023 by 42%. The presence of giant key players who are continuously working to expand their business worldwide making the commercialization of the products. Also, an increase in clinical surgeries to use more medication is accelerating the development of novel treatments. The highly developed healthcare infrastructure and increasing awareness are contributing to market growth.
Europe is expected to hold the second largest market share, due to a rise in health care infrastructure and expenditure, The increasing number of populations suffering from fungal infection is boosting this market to grow in the European region.
Furthermore, Asia-Pacific is witnessing the highest CAGR in the coming years. The increasing incidence of fungal infection is giving reason to the government of India to come up with apublic-private partnership giving more opportunities for key players to invest in the growth of the region.
Key questions answered by this report.
- Top market players contributing to the revenue?
- Trending strategies by the players?
- Which region will be the leading one in the forecast period?
- Factors that drive the Global Anti-Fungal Drugs Market?
- Which factors will affect the Global Anti-Fungal DrugsMarket?
- How Covid-19 pandemic impacted the growth of the GlobalAnti-Fungal DrugsMarket?
- Which Segment accounted for the Global Anti-Fungal Drugs Market shares?
Frequently Asked Questions (FAQ) :
Interested in this report?
The Global Anti-Fungal Drugs Market was valued at USD 16.5 Billion in 2023 and is estimated to reach USD21.93 Billion by 2032, growing at a CAGR of 3.54% from 2023 to 2032.
TOC